Grey A - Search Results

1

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP. Broom RJ, et al. Among authors: grey a. Clin Genitourin Cancer. 2015 Feb;13(1):50-8. doi: 10.1016/j.clgc.2014.07.002. Epub 2014 Jul 15. Clin Genitourin Cancer. 2015. PMID: 25163397 Clinical Trial.

2

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR. Bolland MJ, et al. J Clin Endocrinol Metab. 2007 Apr;92(4):1283-8. doi: 10.1210/jc.2006-2216. Epub 2007 Jan 16. J Clin Endocrinol Metab. 2007. PMID: 17227801 Clinical Trial.

3

Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Callon KE, Gamble GD, Reid IR. Bolland MJ, et al. J Bone Miner Res. 2008 Aug;23(8):1304-8. doi: 10.1359/jbmr.080312. J Bone Miner Res. 2008. PMID: 18627266 Free article. Clinical Trial.

4

Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.

Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR. Grey A, et al. J Bone Miner Res. 2010 Oct;25(10):2251-5. doi: 10.1002/jbmr.103. J Bone Miner Res. 2010. PMID: 20499349 Free article. Clinical Trial.

5

Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.

Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Grey A, et al. J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9. J Clin Endocrinol Metab. 2012. PMID: 22072741 Clinical Trial.

6

Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR. Grey A, et al. Bone. 2012 Jun;50(6):1389-93. doi: 10.1016/j.bone.2012.03.016. Epub 2012 Mar 24. Bone. 2012. PMID: 22465268 Clinical Trial.

7

Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.

Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, Reid IR. Grey A, et al. J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009. J Bone Miner Res. 2014. PMID: 23761303 Free article. Clinical Trial.

8

Adverse skeletal effects of drugs - beyond Glucocorticoids.

O'Sullivan S, Grey A. O'Sullivan S, et al. Among authors: grey a. Clin Endocrinol (Oxf). 2015 Jan;82(1):12-22. doi: 10.1111/cen.12549. Epub 2014 Jul 28. Clin Endocrinol (Oxf). 2015. PMID: 25039381 Review.

9

Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.

Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Grey A, et al. CMAJ. 2017 Sep 11;189(36):E1130-E1136. doi: 10.1503/cmaj.161207. CMAJ. 2017. PMID: 28893875 Free PMC article. Clinical Trial.

10

Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.

Grey A, Horne A, Gamble G, Mihov B, Reid IR, Bolland M. Grey A, et al. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgaa062. doi: 10.1210/clinem/dgaa062. J Clin Endocrinol Metab. 2020. PMID: 32016386 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

747 results

Search Page